3,4-dihydroxyphenylacetic acid has been researched along with dynorphins in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (21.43) | 18.7374 |
| 1990's | 8 (57.14) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lookingland, KJ; Manzanares, J; Moore, KE; Wagner, EJ | 2 |
| Gunne, L; Häggström, JE; Johansson, PE; Terenius, L | 1 |
| Bao, WL; Sun, FY; Tong, JF; Zhang, AZ; Zhang, LM | 1 |
| Herrera-Marschitz, M; Hökfelt, T; Reid, M; Terenius, L; Ungerstedt, U | 1 |
| Sivam, SP | 2 |
| Cosi, C; Iyengar, S; Kim, HS; Wood, PL | 1 |
| Funada, M; Misawa, M; Nagase, H; Narita, M; Suzuki, T | 1 |
| Godukhin, O; Goiny, M; Herrera-Marschitz, M; Hökfelt, T; Kehr, J; Nylander, I; Pettersson, E; Shou, HZ; Terenius, L; Ungerstedt, U; You, ZB | 1 |
| Durham, RA; Johnson, JD; Lookingland, KJ; Moore, KE | 1 |
| Chen, JF; Cuellar, B; Fredduzzi, S; Impagnatiello, F; Monopoli, A; Moratalla, R; Ongini, E; Schwarzschild, MA; Xu, K | 1 |
| Li, J; Lu, XQ; Su, RB; Wei, XL; Wu, N; Zheng, JQ | 1 |
| Caboni, P; Carboni, E; Carta, AR; Frau, L; Garau, A; Ibba, M; Schintu, N | 1 |
14 other study(ies) available for 3,4-dihydroxyphenylacetic acid and dynorphins
| Article | Year |
|---|---|
Effects of immunoneutralization of dynorphin1-17 and dynorphin1-8 on the activity of central dopaminergic neurons in the male rat.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; 3,4-Dihydroxyphenylacetic Acid; Analgesics; Animals; Brain Chemistry; Dopamine; Dynorphins; Injections, Intraventricular; Male; Median Eminence; Neurons; Peptide Fragments; Pyrrolidines; Rats | 1992 |
Neuropeptide changes in a primate model (Cebus apella) for tardive dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Chemistry; Cebus; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Glutamate Decarboxylase; Homovanillic Acid; Male; Neuropeptides; Substance P; Substantia Nigra | 1990 |
[Antagonistic effect of phencyclidine on cerebral ischemic damage of rats].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Brain Ischemia; Catecholamines; Cerebral Cortex; Dopamine; Dynorphins; Hydroxyindoleacetic Acid; In Vitro Techniques; Male; Phencyclidine; Rats; Rats, Inbred Strains | 1991 |
Differential modulation of striatal dopamine release by intranigral injection of gamma-aminobutyric acid (GABA), dynorphin A and substance P.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Dynorphins; gamma-Aminobutyric Acid; Homovanillic Acid; Injections, Intraventricular; Male; Rats; Rats, Inbred Strains; Substance P | 1988 |
Cocaine selectively increases striatonigral dynorphin levels by a dopaminergic mechanism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cocaine; Corpus Striatum; Dopamine; Dynorphins; Endorphins; Enkephalin, Methionine; Hydroxyindoleacetic Acid; Neuropeptides; Rats; Receptors, Dopamine; Serotonin; Substance P; Substantia Nigra | 1989 |
The endogenous kappa agonist, dynorphin(1-13), does not alter basal or morphine-stimulated dopamine metabolism in the nigrostriatal pathway of the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Corticosterone; Dopamine; Dynorphins; Homovanillic Acid; Male; Morphine; Peptide Fragments; Rats; Rats, Inbred Strains; Substantia Nigra | 1987 |
Influence of monoamine oxidase inhibitors on striatonigral dynorphin system: a study with deprenyl and clorgyline.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dopamine; Dynorphins; Hydroxyindoleacetic Acid; Male; Monoamine Oxidase Inhibitors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Selegiline; Serotonin; Substantia Nigra | 1993 |
Blockade of morphine reward through the activation of kappa-opioid receptors in mice.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; 3,4-Dihydroxyphenylacetic Acid; Analgesics; Animals; Apomorphine; Conditioning, Operant; Dopamine; Dynorphins; Homovanillic Acid; Injections, Subcutaneous; Limbic System; Male; Mice; Mice, Inbred Strains; Morphine; Motivation; Naltrexone; Peptide Fragments; Prosencephalon; Pyrrolidines; Receptors, Opioid, kappa; Reward | 1993 |
Neurochemical evidence that estrogen-induced suppression of kappa-opioid-receptor-mediated regulation of tuberoinfundibular dopaminergic neurons is prolactin-independent.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Brain Chemistry; Dopamine; Dynorphins; Estrogens; Female; Hydrazines; Hypothalamic Hormones; Injections, Intraventricular; Median Eminence; Naltrexone; Nerve Endings; Neurons; Ovariectomy; Peptide Fragments; Prolactin; Rats; Receptors, Opioid, kappa | 1994 |
Modulation of neurotransmitter release by cholecystokinin in the neostriatum and substantia nigra of the rat: regional and receptor specificity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aspartic Acid; Cholecystokinin; Dopamine; Dynorphins; Endorphins; gamma-Aminobutyric Acid; Glutamic Acid; Homovanillic Acid; Kinetics; Male; Neostriatum; Neurons; Neurotransmitter Agents; Organ Specificity; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Substantia Nigra; Time Factors | 1996 |
Evidence that D2 receptor-mediated activation of hypothalamic tuberoinfundibular dopaminergic neurons in the male rat occurs via inhibition of tonically active afferent dynorphinergic neurons.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; 3,4-Dihydroxyphenylacetic Acid; Afferent Pathways; Analgesics; Animals; Cerebral Ventricles; Dihydroxyphenylalanine; Dopa Decarboxylase; Dopamine; Dopamine Agonists; Dynorphins; Hypothalamus; Hypothalamus, Middle; Injections, Intraperitoneal; Injections, Intraventricular; Limbic System; Male; Median Eminence; Naltrexone; Narcotic Antagonists; Neurons; Nucleus Accumbens; Prolactin; Pyrrolidines; Quinolines; Rats; Receptors, Dopamine D2; Receptors, Opioid, kappa | 1996 |
Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adaptation, Physiological; Animals; Autoradiography; Behavior, Animal; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Administration Schedule; Dynorphins; Female; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Knockout; Motor Activity; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease, Secondary; Receptor, Adenosine A2A; Receptors, Purinergic P1; RNA, Messenger; Substantia Nigra | 2002 |
Agmatine inhibits morphine-induced locomotion sensitization and morphine-induced changes in striatal dopamine and metabolites in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic alpha-Antagonists; Agmatine; Analysis of Variance; Animals; Behavior, Animal; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Dynorphins; Gene Expression Regulation; Homovanillic Acid; Idazoxan; Locomotion; Male; Morphine; Narcotics; Rats; Rats, Wistar; Time Factors | 2007 |
PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catalepsy; CD11b Antigen; Chromatography, High Pressure Liquid; Chronic Disease; Disease Models, Animal; Dopamine; Drug Interactions; Dynorphins; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Globus Pallidus; Locomotion; Male; Mice; Mice, Inbred C57BL; Motor Activity; MPTP Poisoning; PPAR gamma; Psychomotor Performance; RNA, Messenger; Rosiglitazone; Smell; Tandem Mass Spectrometry; Thiazolidinediones; Tyrosine 3-Monooxygenase | 2009 |